How Much Is Too Much? Treating Frail and Older Patients with Multiple Myeloma

The management of older and frail patients with multiple myeloma requires a careful balance between maximizing disease control and minimizing treatment-related toxicity. This session will explore contemporary approaches to individualized therapy selection, emphasizing the growing role of frailty assessment in guiding treatment intensity beyond chronological age alone. Faculty will review recent clinical trial data evaluating frailty-adapted regimens, anti-CD38–based combinations, dexamethasone-sparing strategies, and dynamic treatment modification based on changing patient fitness. Key considerations surrounding quality of life, functional status, treatment discontinuation, and toxicity management will be discussed. Attendees will gain practical insights into optimizing outcomes while avoiding both overtreatment and undertreatment in this increasingly important patient population.